{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T05:24:08Z","timestamp":1783056248610,"version":"3.54.6"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,3,19]],"date-time":"2024-03-19T00:00:00Z","timestamp":1710806400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,3,19]],"date-time":"2024-03-19T00:00:00Z","timestamp":1710806400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1007\/s10620-024-08380-2","type":"journal-article","created":{"date-parts":[[2024,3,19]],"date-time":"2024-03-19T11:02:30Z","timestamp":1710846150000},"page":"1602-1607","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Some Drugs Have Two Faces: Paradoxical Colitis in a Patient with Psoriatic Arthritis Previously Treated with Etanercept and IL-17 Inhibitors"],"prefix":"10.1007","volume":"69","author":[{"given":"Sandy","family":"Huynh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudharshan","family":"Achalu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rani","family":"Berry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janice","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cindy X.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Gubatan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice G.","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,19]]},"reference":[{"key":"8380_CR1","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1053\/j.gastro.2023.07.003","volume":"165","author":"JD Lewis","year":"2023","unstructured":"Lewis JD, Parlett LE, Jonsson Funk ML, Brensinger C, Pate V, Wu Q, Dawwas GK, Weiss A, Constant BD, McCauley M, Haynes K, Yang JY, Schaubel DE, Hurtado-Lorenzo A, Kappelman MD. Incidence, Prevalence, and Racial and Ethnic Distribution of Inflammatory Bowel Disease in the United States. Gastroenterology 2023;165:1197-1205.e2. https:\/\/doi.org\/10.1053\/j.gastro.2023.07.003.","journal-title":"Gastroenterology"},{"key":"8380_CR2","doi-asserted-by":"publisher","first-page":"91","DOI":"10.3748\/wjg.v20.i1.91","volume":"20","author":"Y-Z Zhang","year":"2014","unstructured":"Zhang Y-Z. Inflammatory bowel disease: Pathogenesis. World Journal of Gastroenterology 2014;20:91. https:\/\/doi.org\/10.3748\/wjg.v20.i1.91.","journal-title":"World Journal of Gastroenterology"},{"key":"8380_CR3","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1001\/jamadermatol.2018.3631","volume":"154","author":"Y Fu","year":"2018","unstructured":"Fu Y, Lee C-H, Chi C-C. Association of Psoriasis With Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. JAMA Dermatology 2018;154:1417. https:\/\/doi.org\/10.1001\/jamadermatol.2018.3631.","journal-title":"JAMA Dermatology"},{"key":"8380_CR4","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.3390\/life13081779","volume":"13","author":"IR Mihai","year":"2023","unstructured":"Mihai IR, Burlui AM, Rezus II, Mihai C, Macovei LA, Cardoneanu A, Gavrilescu O, Dranga M, Rezus E. Inflammatory Bowel Disease as a Paradoxical Reaction to Anti-TNF-\u03b1 Treatment\u2014A Review. Life 2023;13:1779. https:\/\/doi.org\/10.3390\/life13081779.","journal-title":"Life"},{"key":"8380_CR5","doi-asserted-by":"publisher","first-page":"1124628","DOI":"10.3389\/fphar.2023.1124628","volume":"14","author":"Z Deng","year":"2023","unstructured":"Deng Z, Wang S, Wu C, Wang C. IL-17 inhibitor-associated inflammatory bowel disease: A study based on literature and database analysis. Frontiers in Pharmacology 2023;14:1124628. https:\/\/doi.org\/10.3389\/fphar.2023.1124628.","journal-title":"Frontiers in Pharmacology"},{"key":"8380_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtauto.2021.100104","volume":"4","author":"S Akiyama","year":"2021","unstructured":"Akiyama S, Sakuraba A. Distinct roles of interleukin-17 and T helper 17 cells among autoimmune diseases. Journal of Translational Autoimmunity 2021;4:100104. https:\/\/doi.org\/10.1016\/j.jtauto.2021.100104.","journal-title":"Journal of Translational Autoimmunity"},{"key":"8380_CR7","doi-asserted-by":"publisher","unstructured":"Wang, J., Bhatia, A., Cleveland, N. K., Gupta, N., Dalal, S., Rubin, D. T., & Sakuraba, A. (2018). Rapid onset of inflammatory bowel disease after receiving secukinumab infusion. ACG Case Reports Journal, 5, e56. https:\/\/doi.org\/10.14309\/crj.2018.56","DOI":"10.14309\/crj.2018.56"},{"key":"8380_CR8","doi-asserted-by":"publisher","unstructured":"Fieldhouse, K. A., Ukaibe, S., Crowley, E. L., Khanna, R., O\u2019Toole, A., & Gooderham, M. J. (2020). Inflammatory bowel disease in patients with psoriasis treated with interleukin-17 inhibitors. Drugs in Context, 9, 2020-2\u20131. https:\/\/doi.org\/10.7573\/dic.2020-2-1","DOI":"10.7573\/dic.2020-2-1"},{"key":"8380_CR9","doi-asserted-by":"publisher","unstructured":"Haidari, W., Al-Naqshabandi, S., Ahn, C. S., Bloomfeld, R. S., & Feldman, S. R. (2019). Asymptomatic Crohn\u2019s disease identified in a patient being treated with secukinumab: A case report. SAGE Open Medical Case Reports, 7, 2050313X1989358. https:\/\/doi.org\/10.1177\/2050313X19893580","DOI":"10.1177\/2050313X19893580"},{"key":"8380_CR10","doi-asserted-by":"publisher","first-page":"2719","DOI":"10.3390\/ijms22052719","volume":"22","author":"D Jang","year":"2021","unstructured":"Jang D, Lee A-H, Shin H-Y, Song H-R, Park J-H, Kang T-B, Lee S-R, Yang S-H. The role of Tumor Necrosis Factor Alpha (TNF-\u03b1) in autoimmune disease and current TNF-\u03b1 inhibitors in therapeutics. International Journal of Molecular Sciences 2021;22:2719. https:\/\/doi.org\/10.3390\/ijms22052719.","journal-title":"International Journal of Molecular Sciences"},{"key":"8380_CR11","doi-asserted-by":"publisher","unstructured":"Tolu, S., Rezvani, A., Hindioglu Dogan, N., & \u00c7alk\u0131n Korkmaz, M. (2018). Etanercept-induced Crohn\u2019s disease in ankylosing spondylitis: A case report and review of the literature. Rheumatology International, 38. https:\/\/doi.org\/10.1007\/s00296-018-4165-3","DOI":"10.1007\/s00296-018-4165-3"},{"key":"8380_CR12","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/apt.15370","volume":"50","author":"J Korzenik","year":"2019","unstructured":"Korzenik J, Larsen MD, Nielsen J, Kjeldsen J, N\u00f8rg\u00e5rd BM. Increased risk of developing Crohn\u2019s disease or ulcerative colitis in 17 018 patients while under treatment with anti-TNF\u03b1 agents, particularly etanercept, for autoimmune diseases other than inflammatory bowel disease. Alimentary Pharmacology & Therapeutics 2019;50:289\u2013294. https:\/\/doi.org\/10.1111\/apt.15370.","journal-title":"Alimentary Pharmacology & Therapeutics"},{"issue":"8","key":"8380_CR13","first-page":"453","volume":"18","author":"P Santiago","year":"2022","unstructured":"Santiago P, Braga-Neto MB, Loftus EV. Novel Therapies for Patients With Inflammatory Bowel Disease. Gastroenterology & Hepatology 2022;18:453\u2013465.","journal-title":"Gastroenterology & Hepatology"},{"key":"8380_CR14","unstructured":"Ranasinghe, I. R., & Hsu, R. (2023). Crohn Disease. In StatPearls. StatPearls Publishing. http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK436021\/"},{"key":"8380_CR15","unstructured":"Adverse drug reaction probability scale (Naranjo) in drug induced liver injury. (2012). In LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. National Institute of Diabetes and Digestive and Kidney Diseases. http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK548069\/"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-024-08380-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10620-024-08380-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-024-08380-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T16:10:47Z","timestamp":1715875847000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10620-024-08380-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,19]]},"references-count":15,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["8380"],"URL":"https:\/\/doi.org\/10.1007\/s10620-024-08380-2","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,19]]},"assertion":[{"value":"6 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}